Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 23 Leukemia, Lymphocytic, Chronic, B-Cell 16 Lymphoma, Mantle-Cell 14 Lymphoma, Follicular 11 Waldenstrom Macroglobulinemia 8 Lymphoma 7 Lymphoma, B-Cell, Marginal Zone 5 Lymphoma, B-Cell 5 Recurrence 4 Lymphoma, Non-Hodgkin 3 Neoplasms 1 Multiple Myeloma 1 Lymphohistiocytosis, Hemophagocytic 1 Leukemia, B-Cell 1 Leukemia 1 Intraocular Lymphoma 1 Dendritic Cell Sarcoma, Interdigitating 1 Cardiovascular Diseases 1

Interventions

Rituximab 15 Cyclophosphamide 15 Peripheral Blood Stem Cell Transplantation 14 fludarabine phosphate 11 Whole-Body Irradiation 11 Mycophenolic Acid 8 Etoposide 8 Methotrexate 7 Filgrastim 7 Cyclosporine 7 Lenalidomide 6 Dexamethasone 6 Busulfan 6 Tacrolimus 5 Radiotherapy 5 Cytarabine 5 Carboplatin 5 Thiotepa 4 Melphalan 4 Transplantation 3 Therapeutics 3 Granulocyte Colony-Stimulating Factor 3 Flow Cytometry 3 Calcium Dobesilate 3 Bortezomib 3 Antilymphocyte Serum 3 pegfilgrastim 2 etoposide phosphate 2 Psychiatric Rehabilitation 2 Polymerase Chain Reaction 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Intraocular Lymphoma × zanubrutinib × Clear all

NCT06973811 2025-05-20

ZR-MTX

Peking Union Medical College Hospital

Phase 2 Not yet recruiting

Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡